Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Gains from Investment Securities (2019 - 2021)

Benitec Biopharma (BNTC) has disclosed Gains from Investment Securities for 3 consecutive years, with $794000.0 as the latest value for Q3 2021.

  • Quarterly Gains from Investment Securities changed N/A to $794000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $794000.0 through Jun 2022, changed N/A year-over-year, with the annual reading at $794000.0 for FY2022, N/A changed from the prior year.
  • Gains from Investment Securities hit $794000.0 in Q3 2021 for Benitec Biopharma, up from -$580000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $794000.0 in Q3 2021 to a low of -$580000.0 in Q1 2020.
  • Historically, Gains from Investment Securities has averaged $198250.0 across 3 years, with a median of $289500.0 in 2019.